These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19193611)

  • 1. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.
    Brousseau ME; Millar JS; Diffenderfer MR; Nartsupha C; Asztalos BF; Wolfe ML; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
    J Lipid Res; 2009 Jul; 50(7):1456-62. PubMed ID: 19193611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
    Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of torcetrapib on the progression of coronary atherosclerosis.
    Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
    N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
    Bellanger N; Julia Z; Villard EF; El Khoury P; Duchene E; Chapman MJ; Fournier N; Le Goff W; Guerin M
    Atherosclerosis; 2012 Mar; 221(1):160-8. PubMed ID: 22265126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.
    Diffenderfer MR; Brousseau ME; Millar JS; Barrett PH; Nartsupha C; Schaefer PM; Wolfe ML; Dolnikowski GG; Rader DJ; Schaefer EJ
    J Lipid Res; 2012 Jun; 53(6):1190-9. PubMed ID: 22474066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
    Catalano G; Julia Z; Frisdal E; Vedie B; Fournier N; Le Goff W; Chapman MJ; Guerin M
    Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):268-75. PubMed ID: 19038848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Cohn JS; Wilson A; Wolfe ML; Nartsupha C; Schaefer PM; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    J Lipid Res; 2008 Mar; 49(3):543-9. PubMed ID: 18033754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
    Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM
    Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of torcetrapib in patients at high risk for coronary events.
    Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
    N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
    Barter PJ; Rye KA; Tardif JC; Waters DD; Boekholdt SM; Breazna A; Kastelein JJ
    Circulation; 2011 Aug; 124(5):555-62. PubMed ID: 21804130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
    Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
    Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CETP inhibitors to increase HDL cholesterol levels.
    Tall AR
    N Engl J Med; 2007 Mar; 356(13):1364-6. PubMed ID: 17387130
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
    Yvan-Charvet L; Matsuura F; Wang N; Bamberger MJ; Nguyen T; Rinninger F; Jiang XC; Shear CL; Tall AR
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1132-8. PubMed ID: 17322101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.